الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 113 |  |  |
| | | from | 113 | | |
Abstract
Diffuse large B-cell lymphoma (DLBCL) is considered a morphologically and biologically heterogeneous disease which is reflected on its highly variable clinical course and markedly diversified outcomes. This heterogeneity encouraged numerous investigators to study the biology of DLBCL, with focus on whether it could be further subdivided into different entities.
The era of gene expression profiling (GEP) studies has shown that DLBCL cases can be reproducibly divided into prognostically important subtypes either originating from germinal center B cells (GCB) or activated B cells (ABC). Many studies have shown an inferior outcome for the latter group. Moreover, cell-of-origin- focused studies, recognized that aberrant MYC and BCL2 expression can have poor outcome. This encouraged more studies evaluating morphological, immunohistochemical and molecular characteristics of DLBCL in order to discover new outcome predictors and moreover, to select candidates for a more aggressive therapy.
In the present study, the 52 included cases of DLBCL were classified using the available and more applicable pathological approaches including morphological features, germinal center differentiation and double/triple hit expression status. These approaches were evaluated in relation to each other and to other clinicopathological parameters of tumor as age, sex, site of the tumor (nodal/extranodal) and tumor stage.